MAS1 and metabolic dysfunction-associated steatotic liver disease: Together with our more recently research on ACE2/Ang-(1–7)/Mas axis can inhibit hepatic insulin resistance, our current findings suggest that ACE2/Ang-(1–7)/Mas axis is a potential target for drug therapy for NAFLD.